TY - JOUR
T1 - Developments in the Management of Severe Asthma in Children and Adolescents
T2 - Focus on Dupilumab and Tezepelumab
AU - van Dijk, Yoni E.
AU - Rutjes, Niels W.
AU - Golebski, Korneliusz
AU - Şahin, Havva
AU - Hashimoto, Simone
AU - Maitland-van der Zee, Anke-Hilse
AU - Vijverberg, Susanne J. H.
N1 - Funding Information: S.J.H.V. is PI of the PERMEABLE consortium. The PERMEABLE consortium is supported by ZonMW (project number: 456008004), the Swedish Research Council (project number 2018-05619), the Ministry of Education, Science and Sport of the Republic of Slovenia (contract number C3330-19-252012), and the German Ministry of Education and Research (BMBF) (project number FKZ01KU1909A), under the frame of the ERA PerMed JTC 2018 Call. Furthermore, she is PI of the PANDA study (supported by Lung Foundation Netherlands, YI grant: 6.2.18.244JO). Funding Information: Real-world experiences from a severe asthma clinic in the UK showed that home administration of omalizumab and mepolizumab in children (6–18 years) was feasible and did not decrease the quality of care []. Sixteen out of the 23 families with children who received biologic treatment were willing to administer the drug at home. Administration by patients or caregivers was supported by video calls. During 2 out of 75 occasions, the biologic was administered inaccurately; however, due to the video supervision, these issues were resolved and there were no adverse effects. Publisher Copyright: © 2023, The Author(s).
PY - 2023/11
Y1 - 2023/11
N2 - Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been developed to treat severe asthma, including monoclonal antibodies (biologics) targeting inflammatory mediators. Biologics that are currently approved to treat children (≥ 6 years of age) or adolescents (≥ 12 years of age) with severe asthma include: anti-immunoglobulin E (omalizumab), anti-interleukin (IL)-5 (mepolizumab), anti-IL5 receptor (benralizumab), anti-IL4/IL13 receptor (dupilumab), and antithymic stromal lymphopoietin (TSLP) (tezepelumab). However, access to these targeted treatments varies across countries and relies on few and crude indicators. There is a need for better treatment stratification to guide which children might benefit from these treatments. In this narrative review we will assess the most recent developments in the treatment of severe pediatric asthma, as well as potential biomarkers to assess treatment efficacy for this patient population.
AB - Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been developed to treat severe asthma, including monoclonal antibodies (biologics) targeting inflammatory mediators. Biologics that are currently approved to treat children (≥ 6 years of age) or adolescents (≥ 12 years of age) with severe asthma include: anti-immunoglobulin E (omalizumab), anti-interleukin (IL)-5 (mepolizumab), anti-IL5 receptor (benralizumab), anti-IL4/IL13 receptor (dupilumab), and antithymic stromal lymphopoietin (TSLP) (tezepelumab). However, access to these targeted treatments varies across countries and relies on few and crude indicators. There is a need for better treatment stratification to guide which children might benefit from these treatments. In this narrative review we will assess the most recent developments in the treatment of severe pediatric asthma, as well as potential biomarkers to assess treatment efficacy for this patient population.
UR - http://www.scopus.com/inward/record.url?scp=85169540139&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s40272-023-00589-4
DO - https://doi.org/10.1007/s40272-023-00589-4
M3 - Review article
C2 - 37658954
SN - 1174-5878
VL - 25
SP - 677
EP - 693
JO - Paediatric drugs
JF - Paediatric drugs
IS - 6
ER -